Related Experiment Video
Updated: Sep 21, 2026
Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method
Published on: August 2, 2021
Anterior cingulate GABA and functional connectivity associated with initial treatment response in first-episode
Tianhao Gao1, Robert C Smith2, Xuan Li1
1Division of Psychotic Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, 200030, China; Clinical Center for Psychotic Disorders, National Center for Mental Disorders, Shanghai, 200030, China.
Background:
The anterior cingulate cortex (ACC) is implicated in schizophrenia, and gamma aminobutyric acid (GABA) in the ACC may differentially affect functional connectivity in patients. However, its association with treatment response remains poorly understood. Here, we examined their relationship and their association with treatment response in patients with differential efficacy.
Methods:
This study included 87 first-episode schizophrenia patients who underwent MRI scans to evaluate functional connectivity and neurotransmitter levels in the ACC. Participants were randomized to one antipsychotic and assessed for symptom severity at baseline and week 8, with them categorized into first trial response (FTR) group (n = 52) and first trial failed (FTF) group (n = 35) based on treatment response.
Results:
Our results revealed GABA levels in the ACC were significantly higher in FTR than FTF patients, and indicated that higher GABA levels were a significant associated with for clinical response. Hyperactive functional connectivity was found in the visual network in FTF compared to FTR. In the FTF, significant positive correlations were found between GABA and functional connectivity of the ACC.
Conclusions:
Our findings highlight the importance of ACC GABA levels, and functional connectivity of the ACC, in modulating antipsychotic drug response in schizophrenia patients. Furthermore, the positive correlation of GABA and functional connectivity in FTF patients suggest that the function of GABA may be altered in some respects from an inhibitory to a facilitating neurochemistry in non-responding schizophrenic patients. Whether supplementation with GABA or GABA receptor agonists could improve clinical response further investigation in future studies.
